As of the latest Form 4 filed Jan 21, 2026.
What Olema Pharmaceuticals Inc insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 34 most recent filings for OLMA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-01-21 | 2026-01-20 | Harmon Cyrus Director | SSale | −10.0K | $26.88 | $269K | No | Form 4 ↗ |
| 2026-01-16 | 2026-01-14 | Harmon Cyrus Director | SSale | −3.49K | $29.12 | $102K | No | Form 4 ↗ |
| 2026-01-15 | 2026-01-15 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | SSale | −100K | $28.73 | $2.87M | No | Form 4 ↗ |
| 2026-01-15 | 2026-01-13 | Kovacs Shane William Charles, CH. OPERATING & FINANCIAL OFF. | SSale | −3.82K | $28.01 | $107K | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-14 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | SSale | −35.0K | $28.99 | $1.01M | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-14 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −15.0K | $28.60 | $429K | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-14 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | MExercise | +50.0K | $4.87 | $244K | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-13 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −200.00 | $28.49 | $5.70K | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-13 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −49.8K | $27.60 | $1.37M | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-13 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | MExercise | +50.0K | $4.87 | $244K | No | Form 4 ↗ |
| 2026-01-14 | 2026-01-12 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −10.0K | $28.34 | $283K | No | Form 4 ↗ |
| 2025-12-30 | 2025-12-26 | Bohen Sean President and CEO | GGift | −8.50K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-29 | 2025-12-22 | Harmon Cyrus Director | SSale | −2.88K | $28.53 | $82.2K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-23 | Zojwalla Naseem Chief Medical Officer | SSale | −99.5K | $27.66 | $2.75M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-23 | Zojwalla Naseem, Chief Medical Officer | MExercise | +50.0K | $7.02 | $351K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-22 | Zojwalla Naseem, Chief Medical Officer | SSale | −100K | $28.04 | $2.80M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-22 | Zojwalla Naseem, Chief Medical Officer | MExercise | +7.18K | $7.02 | $50.4K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-22 | Zojwalla Naseem, Chief Medical Officer | MExercise | +42.8K | $15.25 | $653K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Zojwalla Naseem, Chief Medical Officer | SSale | −12.9K | $28.93 | $374K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Zojwalla Naseem, Chief Medical Officer | SSale | −57.1K | $28.03 | $1.60M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Zojwalla Naseem, Chief Medical Officer | MExercise | +40.0K | $15.25 | $610K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | GGift | −9.00K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −6.05K | $31.39 | $190K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −43.7K | $30.40 | $1.33M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | Myles David C., CH. DISCOV. & NON-CLIN DEV OFF | SSale | −1.23K | $28.08 | $34.4K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T Director | SSale | −41.8K | $30.48 | $1.28M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | SSale | −193K | $29.71 | $5.74M | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | SSale | −29.9K | $28.83 | $862K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | MExercise | +12.1K | $4.08 | $49.2K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | MExercise | +21.5K | $7.84 | $169K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | MExercise | +21.5K | $3.61 | $77.7K | No | Form 4 ↗ |
| 2025-12-23 | 2025-12-19 | CLARK IAN T, Director | MExercise | +210K | $4.41 | $924K | No | Form 4 ↗ |
| 2025-12-09 | 2025-12-08 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | GGift | −75.0K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | Harmon Cyrus Director | SSale | −15.0K | $9.51 | $143K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also OLMA’s full analysis or the market-wide insider trading feed. The tabs above jump to OLMA’s other SEC data.
Source: SEC Form 4 filings for OLMA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.